MoonLake Immunotherapeutics Class A MLTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MLTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $40.93
- Day Range
- $41.20–42.87
- 52-Week Range
- $20.66–64.98
- Bid/Ask
- $42.21 / $42.35
- Market Cap
- $2.66 Bil
- Volume/Avg
- 110,551 / 478,742
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company derives maximum revenue from United Kingdoms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 50
- Website
- https://www.moonlaketx.com
Comparables
Valuation
|
Metric
|
MLTX
|
ACIU
|
VECT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.99 | 1.29 | 4.95 |
Price/Sales | — | 12.76 | 27.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
MLTX
ACIU
VECT
Financial Strength
|
Metric
|
MLTX
|
ACIU
|
VECT
|
|---|---|---|---|
Quick Ratio | 51.38 | 8.74 | 9.01 |
Current Ratio | 51.59 | 9.22 | 9.14 |
Interest Coverage | — | −313.02 | −41.28 |
Quick Ratio
MLTX
ACIU
VECT
Profitability
|
Metric
|
MLTX
|
ACIU
|
VECT
|
|---|---|---|---|
Return on Assets (Normalized) | −11.20% | −30.01% | −37.23% |
Return on Equity (Normalized) | −12.51% | −33.60% | −44.82% |
Return on Invested Capital (Normalized) | −11.49% | −33.51% | −42.88% |
Return on Assets
MLTX
ACIU
VECT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dvmsxrrjs | Kfp | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nxhnxwll | Gjfbph | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wpkzczqs | Fjmzsz | $98.1 Bil | |
MRNA
| Moderna Inc | Vsrqbrbh | Spjt | $42.2 Bil | |
ARGX
| argenx SE ADR | Xlxfbhf | Qtn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pgfghrww | Zgx | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rzqlcjbzf | Cvtjdd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Clwxjny | Zlljf | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bsrfgxqyq | Bhfkrh | $12.5 Bil | |
INCY
| Incyte Corp | Zhdrtqbc | Spxgxz | $11.7 Bil |